Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer - Measles
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Lung Neoplasms - Measles
Conditions: Keywords
measles-positive NSCLC, measles vaccine, consolidation, Stage 3B with pleural effusion or stage 4 non-small cell lung cancer in remission
Study Type
Interventional
Study Phase
Phase 1/Phase 2
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: attenuated measles vaccine
Type: Biological
Overall Status
Not yet recruiting
Summary
The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with pleural effusion) or metastatic (stage 4) tumors in remission.
Detailed Description
This is a single-institution, non-randomized phase 1/2 study in patients with locally-advanced or metastatic NSCLC in remission after receiving standard systemic chemotherapy of four cycles of combination chemotherapy consisting of four cycles of cisplatin combined with vinorelbine.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 80 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Patients in remission after first-line chemotherapy

Exclusion Criteria:

- Progressive disease
Location
Department of Oncology, Soroka Medical Center
Beer Sheva, Israel
Status: Not yet recruiting
Start Date
March 2009
Sponsors
Soroka University Medical Center
Source
Soroka University Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page